Celgene (CELG) – Company Press Releases
-
MindMed Files Preliminary Proxy Statement for 2023 Annual Meeting
-
Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of its Tender Offers
-
Bristol Myers Squibb Announces Early Participation Results, Upsizing and Early Settlement of Tender Offers
-
Bristol Myers Squibb Announces Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion
-
Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics’ TCR Bispecific Program IMA401
-
INVESTOR ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits filed on behalf of BMY, LSPD, PTON, ZG Investors, Lead Plaintiff Deadlines Set
-
INVESTOR ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits filed on behalf of BMY, CTXS, OWLT, PTON Investors, Lead Plaintiff Deadlines Set
-
INVESTOR ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits filed on behalf of BMY, EAR, HMLP, NVAX Investors, Lead Plaintiff Deadlines Set
-
BMY, EAR, HMLP SHAREHOLDERS - ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action lawsuits filed on behalf of Investors, Lead Plaintiff Deadlines Set
-
FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Bristol-Myers Squibb Company - BMY
-
INVESTOR ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits filed on behalf of BMY, EAR, HYZN, WDH Investors, Lead Plaintiff Deadlines Set
-
INVESTOR ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits filed on behalf of APPH, BMY, EAR, HYZN Investors, Lead Plaintiff Deadlines Set
-
APPH, BMY, EAR, HYZN SHAREHOLDERS - ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action lawsuits filed on behalf of Investors, Lead Plaintiff Deadlines Set
-
Entwistle & Cappucci LLP Files a Securities Class Action Complaint Against Bristol-Myers Squibb Company
-
Bristol Myers Squibb and Celgene Issue Notices of Redemption and Partial Redemption of Certain of Their Senior Notes at “Make Whole” Prices
-
Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion
-
Bristol Myers Squibb Announces Early Participation Results and Early Settlement of Tender Offers for Up to an Aggregate Purchase Price of Up to $4.0 Billion
-
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020
-
Bristol Myers Squibb Announces Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion
-
Cipla Announces Settlement of REVLIMID® (lenalidomide) Capsules Patent Litigation
-
Pentwater Solicits Holders of Bristol-Myers Squibb Contingent Value Rights to Provide Consent to Replace Trustee
-
NexImmune Appoints Sol Barer as Chairman of the Board of Directors
-
NexImmune Appoints Sol Barer as Chairman of the Board of Directors
-
Bristol-Myers Squibb Company Announces Final Results of Exchange Offers for Celgene Corporation Notes
-
Amgen Completes Acquisition Of Otezla® (apremilast)
-
Celgene Announces Plans to Transfer Listing of Celgene’s Contingent Value Rights Following Closing of Acquisition by Bristol-Myers Squibb
-
Bristol-Myers Squibb Completes Acquisition of Celgene, Creating a Leading Biopharma Company
-
Thermo Fisher Scientific Set to Join S&P 100; ServiceNow to Join S&P 500
-
Exelon Corporation to Join the NASDAQ-100 Index Beginning November 21, 2019
-
Exelon Corporation to Join the NASDAQ-100 Index Beginning November 21, 2019
-
Bristol-Myers Squibb Company Announces It Expects No Further Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes
-
Bristol-Myers Squibb Receives Clearance from U.S. Federal Trade Commission for Celgene Acquisition
-
Celgene Receives CHMP Positive Opinion for REVLIMID® (lenalidomide) in Combination With Rituximab for the Treatment of Adult Patients With Previously Treated Follicular Lymphoma
-
Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes
-
Skyhawk Therapeutics Announces a Second Multi-Target Collaboration Agreement with Celgene to Discover and Develop Novel Small Molecules that Modulate RNA Splicing
-
Editas Medicine and Celgene Corporation Amend Existing Collaboration to Develop and Commercialize Autologous and Allogeneic T Cell Medicines for the Treatment of Cancer and Autoimmune Diseases
-
Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes
-
FDA Approves REBLOZYL® (luspatercept-aamt) for the Treatment of Anemia in Adults With Beta Thalassemia Who Require Regular Red Blood Cell Transfusions
-
Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes
-
Antengene Corporation Announces Exclusive Worldwide License to Develop and Commercialize AZD0364
-
Celgene to Present New and Updated Data on Key Hematology Pipeline Therapies at American Society of Hematology (ASH) 2019 Annual Meeting
-
Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes
-
Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes
-
Celgene Reports Third Quarter 2019 Operating and Financial Results
-
Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes
-
Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes
-
Celgene and the Multiple Sclerosis Association of America Take the MS MindShift Initiative and “Brain Bulb” Hot Air Balloon to the Sky at Owl-O-Ween Festival to Educate on Multiple Sclerosis and B
-
State Street Global Advisors Announces Impact of Receiving Payment
-
Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes
-
Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes
Back to CELG Stock Lookup
